Trial · NCT02957682
Results by group112
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 112
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Cognitive Domain Spatial Working Memory (SWM) Strategy Z-Score at Week 96 | Placebo | -0.180 | Standard Error 0.027 | Z-score | |
| Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Cognitive Domain Spatial Working Memory (SWM) Strategy Z-Score at Week 96 | Alirocumab 75 Q2W/Up150 Q2W | -0.200 | Standard Error 0.027 | Z-score | |
| Change From Baseline in CANTAB Cognitive Domain SWM Strategy Raw Score at Week 96 | Placebo | -0.9 | Standard Deviation 4.49 | Units on a Scale | |
| Change From Baseline in CANTAB Cognitive Domain SWM Strategy Raw Score at Week 96 | Alirocumab 75 Q2W/Up150 Q2W | -1.0 | Standard Deviation 4.31 | Units on a Scale | |
| Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol (LDL-C) at Week 12, 24, 48, 72, and 96 | Placebo | Percent change at Week 12 | 0.6 | Standard Error 1.0 | Percent Change |
| Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol (LDL-C) at Week 12, 24, 48, 72, and 96 | Alirocumab 75 Q2W/Up150 Q2W | Percent change at Week 12 | -49.6 | Standard Error 0.9 | Percent Change |
| Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol (LDL-C) at Week 12, 24, 48, 72, and 96 | Placebo | Percent change at Week 24 | 3.0 | Standard Error 1.0 | Percent Change |
| Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol (LDL-C) at Week 12, 24, 48, 72, and 96 | Alirocumab 75 Q2W/Up150 Q2W | Percent change at Week 24 | -54.2 | Standard Error 1.0 | Percent Change |
| Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol (LDL-C) at Week 12, 24, 48, 72, and 96 | Placebo | Percent change at Week 48 | 2.8 | Standard Error 1.1 | Percent Change |
| Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol (LDL-C) at Week 12, 24, 48, 72, and 96 | Alirocumab 75 Q2W/Up150 Q2W | Percent change at Week 48 | -51.4 | Standard Error 1.1 | Percent Change |
| Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol (LDL-C) at Week 12, 24, 48, 72, and 96 | Placebo | Percent change at Week 72 | 2.4 | Standard Error 1.2 | Percent Change |
| Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol (LDL-C) at Week 12, 24, 48, 72, and 96 | Alirocumab 75 Q2W/Up150 Q2W | Percent change at Week 72 | -50.4 | Standard Error 1.2 | Percent Change |
| Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol (LDL-C) at Week 12, 24, 48, 72, and 96 | Placebo | Percent change at Week 96 | 4.0 | Standard Error 1.3 | Percent Change |
| Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol (LDL-C) at Week 12, 24, 48, 72, and 96 | Alirocumab 75 Q2W/Up150 Q2W | Percent change at Week 96 | -46.2 | Standard Error 1.3 | Percent Change |
| Percent Change From Baseline in Apolipoprotein (Apo) B at Week 12, 24, 48, 72, and 96 | Placebo | Percent change at Week 12 | 0.8 | Standard Error 0.7 | Percent Change |
| Percent Change From Baseline in Apolipoprotein (Apo) B at Week 12, 24, 48, 72, and 96 | Alirocumab 75 Q2W/Up150 Q2W | Percent change at Week 12 | -36.7 | Standard Error 0.7 | Percent Change |
| Percent Change From Baseline in Apolipoprotein (Apo) B at Week 12, 24, 48, 72, and 96 | Placebo | Percent change at Week 24 | 2.1 | Standard Error 0.8 | Percent Change |
| Percent Change From Baseline in Apolipoprotein (Apo) B at Week 12, 24, 48, 72, and 96 | Alirocumab 75 Q2W/Up150 Q2W | Percent change at Week 24 | -40.9 | Standard Error 0.8 | Percent Change |
| Percent Change From Baseline in Apolipoprotein (Apo) B at Week 12, 24, 48, 72, and 96 | Placebo | Percent change at Week 48 | 1.1 | Standard Error 0.8 | Percent Change |
| Percent Change From Baseline in Apolipoprotein (Apo) B at Week 12, 24, 48, 72, and 96 | Alirocumab 75 Q2W/Up150 Q2W | Percent change at Week 48 | -39.0 | Standard Error 0.8 | Percent Change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02957682/results